Analyst Coverage

Research reports on Pharmaxis issued by the following organisations are listed below: 

Firm

Analyst

Contact

 

Mark Pachacz (editor)

 

info@bioshares.com.au

 

 

Anubhav Saxena

 

asaxena@bellpotter.com.au

Emerald Financial

 

Alfred Chan

Emerald Financial

 

alfred.chan@emeraldfinancial.com.au

morgans logo3x

 

Derek Jellinek

Iain Wilkie

Scott Power

 

derek.jellinek@morgans.com.au

 

Chris Kallos

 

chris.kallos@mstaccess.com.au

 

Dennis Hulme

 

dhulme@taylorcollison.com.au

01/11/2023

1Q: Refocused Business Cutting Expenses, Progressing Trials

 MST Access
09 /10/2023

Pharmaxis evolves into Syntara: sells mannitol unit; sharpening operational focus and cutting costs

MST Access
06/10/2023

Restructured to Smaller, More Agile Drug Developer

Morgans
05/09/2023

Positive PXS-5505 Preclinical Data Published in Peer-Reviewed Journal

MST Access
22/8/2023

Clinical-stage pipeline continues to advance

Morgans
14/8/2023

Pharmaxis -Meaningful Impact on Bone Marrow in Myelofibrosis Study

Bioshares
21/6/2023

Progressing to Next Stage in Scarring and Myelofibrosis

Taylor Collison
06/06/2023

Mixed Results from Pharmaxis' Scar Treatment Study

Bioshares
25/05/2023

Pleasing Results from Established Scars, Phase 1c – More to Come

MST Access
05/05/2023

3Q: Cash Balance Comfortable as Key Trials Proceed in Tandem

MST Access
01/05/2023

Pharmaxis Phase II Trial Results Approaching

Bioshares
13/04/2023

Useful FDA Feedback Paves Way for New Arm of Lead Clinical Trial

MST Access
30-03-2023

Raising PXS-5505 Profile in New Indication, Synergies with SOC

MST Access
28-03-2023

Pharma's Market

Bell Potter
24-02-2023

Pharmaxis: A Re-Rating Approaching?

Bioshares
20-02-2023

2QFY23 – news flow plentiful in 2023 with data readouts from two major trials

MST Access
27-12-2022

Top 6 Stock Picks for 2023: Will 2023 be the Breakout Year for Pharmaxis?

Bioshares
09-11-2022

1QFY23 Release Shows Diverse Pipeline Continuing to Deliver News Flow 

MST Access
04-11-2022

Pharmaxis Releases Initial Data in Myelofibrosis 

Bioshares
07-10-2022

Encouraging initial efficacy data, adding new programs

Taylor Collison
19-09-2022

Pharmaxis: Can PXS-6302 'Un-scar the

Scar'?

Bioshares
12-09-2022

Pharmaxis Repurposes PXS-4728 for Parkinson's Disease

Bioshares
02-09-2022 New collaboration to study PXS-4728 for early neurodegenerative treatment MST Access
16-August-2022 Building up its short-term cash position Morgans
05-08-2022

Pharmaxis Sells Orbital Technology for US$5 Million

 Bioshares
15-June-2022 Clinical trials on track; news flow ahead MST Access
12-April-2022 Following the Science Morgans
08-April-22 PXS-5505 and PXS-6320 R&D Days Taylor Collison
15-Feb-22 Pharmaxis Update Bioshares
31-Jan-22 Making tracks with concurrent trials; 2Q results announced MST Access
6-Dec-21 New capital extends cash runway MST Access
30-Nov-21 Initiation Report: Pharmaxis - Exploring Efficacy in Cancer and Fibrosis Taylor Collison
24-Nov-21 Updated report Emerald
12-Nov-21 New indication for PXS-5505 MST Access
1-Nov-21 Initiation of Coverage MST Access
18-May-21 Initial report Emerald
19-Apr-21 Karst Peak Continues Investment in Austalia Biotech Bioshares
15-Feb-21 Pharmaxis Makes First Commercial Bronchitol Shipment to USA Bioshares
13-Feb-21 1H21 – Result Summary Bell Potter
7-Jan-21 FDA approval for Bronchitol revamps the business, improves outlook Bell Potter
3-Nov-20 Bronchitol FDA Approval a Turning Point for Pharmaxis Bioshares
7-Sep-20 Boehringer Ends Development of Pharmaxis Compound Bioshares
7-Sep-20 BI terminates agreement, discontinues Bell Potter
19-Aug-20 FDA clears IND for myelofibrosis study Bell Potter
13-Aug-20 FY20 Audited Results - No Material Change  Bell Potter
10-Aug-20 A Big Six Months Ahead for Pharmaxis Bioshares
5-Aug-20 Key catalysts expected in Q4CY20 Bell Potter
22-May-20 COVID-19 impacting timing for key catalysts Bell Potter
4-May-20 Pharmaxis - Multiple Assets to Drive Value Bioshares
24-Feb-20 Pharmaxis Remains Confident of Securing LOXL2 Deal Bioshares
13-Feb-20 1H20 Audited Results - No Material Change Bell Potter
6-Feb-20 Down but not out, with turnaround prospects strong in CY20 Bell Potter